Retevmo：Retevmo® (selpercatinib)

Retevmo® (selpercatinib)

Retevmo(selpercatinib)isanoraltherapythatcanbetakenathomeandisforpeoplewithcertainadvancedcancersthattestpositiveforRET.。其他文章還包含有：「FDAapprovesselpercatinibforRETfusion」、「HowRetevmoWorks」、「Retevmo」、「RETEVMO®(selpercatinib)capsules」、「Selpercatinib(Retevmo)」、「禮來首款RET抑制劑Retevmo轉為正式批准FDA再批用於...」、「第一個RET抑制劑，FDA核准禮來Retevmo用於所有轉移性...」、...

查看更多離開網站

pralsetinib仿單 Selpercatinib

Provide From Google

FDA approves selpercatinib for RET fusion

https://www.fda.gov

The Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age ...

Provide From Google

How Retevmo Works

https://retevmo.lilly.com

Retevmo is a prescription oral therapy that was designed to block the primary driver of tumor growth in RET-positive advanced non-small cell lung cancer (NSCLC ...

Provide From Google

Retevmo

https://chemocare.com

這是什麼藥物？ SELPERCATINIB 可治療特定類型的癌症。其作用方式是阻斷造成癌細胞的蛋白，使其無法生長與增殖。有助於減緩或停止癌細胞的擴散。

Provide From Google

RETEVMO® (selpercatinib) capsules

https://www.accessdata.fda.gov

RETEVMO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene ...

Provide From Google

Selpercatinib (Retevmo)

https://www.ncbi.nlm.nih.gov

Evidence from a clinical trial demonstrated that people with metastatic RET fusion-positive NSCLC treated with Retevmo experienced tumour shrinkage or the ...

Provide From Google